Skip to Main Content

The Food and Drug Administration’s rejection of a gene therapy for hemophilia A on Wednesday surprised many hematology researchers and Wall Street watchers who expected speedy approval for the one-time treatment to end the inherited bleeding disorder. 

For one family in Indianapolis active in the hemophilia patient community, the decision was disappointing, but also appreciated. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!